Alfresa agrees biosimilar venture: Alfresa stock yields 3.07 percent

Published on 10/06/2026 at 12:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose from JPY 740.98 billion to JPY 788.96 billion in fiscal 2027 first quarter. For Alfresa stock, net income was JPY 2.48 billion.

Alfresa, JP3126340003, Illustration mit AI erstellt.

Alfresa Holdings Corporation (JP3126340003) agreed a basic biosimilar venture on October 6, 2026, while Alfresa stock carried a 3.07 percent dividend yield on the Tokyo market. Kabumap listed the agreement alongside a basic agreement covering biosimilar development and manufacturing cooperation.

Biosimilar strategy gains a date

The October 6 disclosures give Alfresa's healthcare expansion a concrete corporate milestone. The company operates across pharmaceutical wholesale distribution, diagnostic reagents and medical equipment, while its newer initiatives extend toward regenerative medicine and biopharmaceutical manufacturing, according to Paasa.

The strategic angle is measured against a mixed earnings profile. In fiscal 2027 first quarter, revenue increased from JPY 740.98 billion in fiscal 2026 fourth quarter to JPY 788.96 billion, a 6.47 percent quarter-on-quarter gain, while operating income declined from JPY 6.43 billion to JPY 5.60 billion.

Revenue grows as profit contracts

Investing.com reported fiscal 2027 first-quarter net income of JPY 2.48 billion and earnings per share of JPY 13.85. Net income was JPY 9.77 billion in the preceding fiscal quarter, so the latest result represents a 74.65 percent quarter-on-quarter decline and leaves the biosimilar initiative competing for attention with near-term profitability.

For the full fiscal year ended March 31, 2026, Alfresa generated JPY 3.10 trillion in revenue and JPY 41.70 billion in net income, compared with JPY 3.00 trillion and JPY 27.40 billion respectively in fiscal 2025, according to Paasa. The comparison shows stronger sales and earnings on a full-year basis even as the first-quarter profit line weakened.

Next results arrive November 5

Investing.com lists November 5, 2026 as Alfresa's next earnings date. That report should provide the next quantified test of whether the company's growth investments can progress while operating profit remains under pressure.

Tokyo quote stays below yearly high

Alfresa was last at JPY 2,245.00 on October 6, 2026 at 3:30 p.m. JST on the Tokyo Stock Exchange, up 0.85 percent versus the prior close of JPY 2,226.00. The 52-week range was JPY 2,070.00 to JPY 2,685.50, putting the latest quote 16.42 percent below the yearly high.